Navigation Links
Kensey Nash and Arthrex Announce European Distribution Agreement for the Cartilage Repair Device
Date:11/9/2010

EXTON, Pa., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a regenerative medicine company, and Arthrex, Inc., a worldwide leader in sports medicine product development and educational services for orthopaedic surgeons, jointly announced an agreement for the European distribution of Kensey Nash's unique Cartilage Repair Device (CRD).

Kensey Nash's CRD technology consists of a biphasic bioresorbable scaffold intended to be implanted at the site of a focal articular cartilage lesion or osteochondral defect in the knee. The product is CE Marked and indicated to support the regeneration of hyaline cartilage and subchondral bone by promoting the correct cellular morphology and structural organization during the healing process. Currently, the CRD is the subject of an FDA approved pilot clinical trial and not yet approved for sale in the US.

Pursuant to the agreement, Kensey Nash will exclusively supply the CRD to Arthrex for European marketing and distribution in accordance with the Company's CE Mark approval.  Other terms of the agreement were not disclosed.

"This partnership represents an important milestone as we continue Kensey Nash's mission as a developer of innovative regenerative medicine products," commented Joseph W. Kaufmann, President and CEO of Kensey Nash. "We look forward to building upon our excellent relationship with our strategic partner Arthrex, a highly respected global leader in the sports medicine industry," he concluded.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology.  The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials.  The Company has an extensive range
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
6. Kensey Nash Announces $30 Million Share Buyback
7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... July 30, 2015 Eisai Inc. announced today ... the United States , European Union and ... MHLW, respectively) for eribulin, for the treatment of patients ... prior chemotherapy for advanced or metastatic disease. ... a pivotal global Phase 3 clinical trial (Study 309), ...
(Date:7/30/2015)... Japan , July 30, 2015 ... of the study to fulfill the post-marketing commitment ... the Pan European Multi-Database Bladder Cancer Risk ... retrospective matched cohort study, conducted in four European ... HCI) with up to 10 years of follow-up. ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... DIEGO, March 21, 2012  Millennium Laboratories announced today ... the course for more responsible and ethical business ... outlines the principles to which Millennium adheres and ... in the pain management industry to adopt. ...
... encourages continuous electronic monitoring, including the use of both ... analgesia (PCA). According to the Institute ... knowledge exist today to prevent errors associated with use ... says , "The solutions are available. We know ...
Cached Medicine Technology:Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3Physician-Patient Alliance for Health & Safety: Hospitals Need to Address PCA Pump Patient Safety 2
(Date:7/31/2015)... York (PRWEB) , ... July ... ... attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now available ... 2015 was well received with a 94% approval rating from the nationwide ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their ... involvement and support of animal welfare organizations is essential to the longevity of their ... year in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets ...
(Date:7/31/2015)... ... ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue for ... the first six months ended June 30, 2015 compared with the same period in ... record-revenue mark of $10.4 million. , “We know what our customers need and want ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t ... the industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International ... event attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... firm, has been recognized in the 2015 Aster Awards national competition for a ... organization serving Ocean City and surrounding communities in Coastal Maryland and Southern Delaware. ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
... Dinoire’s countenance has changed 360 degrees in comparison to how ... the first patient in the world to undergo a// partial ... year ago, combined the dexterity of a 50 member team, ... has recovered very well. ,Miss Dinoire, 39, ...
... Maldives men's volleyball team lost to Chinese Taipei (Taiwan) in ... three of its players were confirmed to have chicken// pox. ... Asian Volleyball Confederation (AVC) said in a statement. ... pox. The disease spreads easily and we have to make ...
... in Mumbai suffers from backache, caused mainly by the poor ... out by Health India, a New Delhi-based non-profit group, the ... Delhi and 77 percent in Mumbai who use public transport ... ,"Bad roads, overcrowded public transport systems, poor quality of ...
... revealed that first time ecstasy users may suffer impaired memory and ... areas of the brain. , ,'We do not know if ... the University of Amsterdam, who led the study. 'Therefore, we cannot ... brain, and people should be informed of this risk.' ...
... the United Kingdom concluded that the UK's National Health ... least// for now. The review was published in the ... series of the Health Technology Assessment Programme, part of ... Kingdom. ,An implantable pump can help heart ...
... you hate being told to sit upright by others, because ... indeed what suits your// body better. Sitting ramrod straight may ... team of Scottish radiologists presented their findings recently at Chicago.They ... monitored using a specialized MRI scanner that could record their ...
Cached Medicine News:Health News:Maldives Volleyball Team Members Affected by Chickenpox 2Health News:Public Transport Causing Backaches in Delhi, Mumbai 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 2Health News:Review Urges Restricted Use Of Devices To Keep Heart Patients Alive 3
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... sulfate (DHEA-S) is the sulfate ester of ... enzymatic conversion of DHEA in adrenal and ... steroid secreted by the adrenal cortex, and ... biosynthesis. DHEA possesses relatively weak androgenic activity, ...
... DSL's unique DHEA-S-7kits ... antiserum targeted against the ... DHEA-S molecule, with no ... DHEA-S Saliva RIA has ...
... is based on the competition principle and ... DHEA-S present in the sample and a ... peroxidase compete for the binding sites of ... wells. After one hour incubation the microtiterplate ...
Medicine Products: